Healthy Male Subjects Clinical Trial
Official title:
A Phase 1 Open-label Study Evaluating the Pharmacokinetics and Mass Balance of [14C] TAS-205 in Healthy Volunteers
Verified date | August 2022 |
Source | Taiho Pharmaceutical Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of [14C]TAS-205 following oral single doses.
Status | Completed |
Enrollment | 6 |
Est. completion date | May 27, 2022 |
Est. primary completion date | June 15, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 20 Years to 39 Years |
Eligibility | Key Inclusion Criteria: 1. Healthy adult male who provided written informed consent to participate in the study 2. Aged 20 years or older and younger than 40 years at the time of informed consent 3. Capable of oral intake. 4. Body weight of 50 kg or more and body mass index of 18.5 or more and less than 25.0 Key Exclusion Criteria 1. Had current or previous hypersensitivity or allergy to drugs 2. Had current or previous drug abuse (including use of illicit drugs) or alcoholism 3. Had any concurrent disease (including symptoms and signs; however, diseases that do not affect valuations in the study such as asymptomatic pollinosis and wart are excluded) 4. Consumed foods or beverages containing the St. John's Wort within 28 days before study drug administration 5. Had blood pressure, pulse rate, and body temperature meeting any of the following at screening: Systolic blood pressure: <90 mmHg or =140 mmHg, Diastolic blood pressure: <40 mmHg or =90 mmHg, Pulse rate: <40 beats per minute (bpm) or =100 bp, Body temperature: 35.0°C or =37.1°C |
Country | Name | City | State |
---|---|---|---|
Japan | A site selected by Taiho Pharmaceutical Co., Ltd. | Tokyo |
Lead Sponsor | Collaborator |
---|---|
Taiho Pharmaceutical Co., Ltd. |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Concentrations of total radioactivity in blood and plasma, plasma TAS-205 concentrations and the pharmacokinetics parameters of TAS-205 | Day 1 to Day 8 | ||
Primary | Radioactivity excretion and excretion rate,cumulative excretion, cumulative excretion rate into urine and feces. | Day 1 to Day 8 | ||
Primary | Radioactivity excretion and excretion rate,cumulative excretion, cumulative excretion rate in all excreta (urine and feces). | Day 1 to Day 8 | ||
Primary | Plasma, urinary, and fecal metabolite profiles of TAS-205 , and structural estimation. | Day 1 to Day 8 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05621447 -
A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects
|
Phase 1 | |
Completed |
NCT02901366 -
Mass Balance Study of FYU-981
|
Phase 2 | |
Not yet recruiting |
NCT01928563 -
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine
|
Phase 1 | |
Completed |
NCT05559554 -
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects
|
Phase 1 | |
Completed |
NCT04512872 -
A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT06111196 -
Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT03317652 -
Effect of Sodium Nitroprusside on Cerebral Blood Flow
|
N/A | |
Completed |
NCT04655872 -
Mass Balance of Oral [14C]TPN171H in Healthy Male Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02609711 -
Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects
|
Phase 1 | |
Withdrawn |
NCT02560363 -
A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT01261260 -
Effect of Uridine on GABA and High Energy Phosphate Levels in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05072028 -
Mass Balance and Biotransformation Study of [14C]DBPR108 in Human
|
Phase 1 | |
Completed |
NCT05446233 -
ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT05275010 -
A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System
|
Phase 1 | |
Completed |
NCT04839744 -
A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT05792917 -
Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT03576651 -
A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01819779 -
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)
|
Phase 1 | |
Completed |
NCT05126784 -
AVT03 With Prolia in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT04850638 -
Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)
|
Phase 1 |